Immuneering (NASDAQ:IMRX) Releases Earnings Results

Immuneering (NASDAQ:IMRX) released its quarterly earnings data on Friday. The company reported ($0.18) earnings per share for the quarter, FiscalAI reports.

Immuneering Stock Performance

Shares of IMRX opened at $5.33 on Friday. The firm has a market capitalization of $344.16 million, a P/E ratio of -2.99 and a beta of 0.46. Immuneering has a 52 week low of $1.10 and a 52 week high of $10.08. The stock has a 50 day moving average price of $5.22 and a two-hundred day moving average price of $6.08.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IMRX. Wall Street Zen upgraded Immuneering from a “sell” rating to a “hold” rating in a research report on Saturday. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Immuneering in a research report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Insider Activity at Immuneering

In related news, Director Thomas J. Schall purchased 21,645 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was acquired at an average cost of $4.67 per share, with a total value of $101,082.15. Following the transaction, the director owned 74,530 shares of the company’s stock, valued at $348,055.10. This represents a 40.93% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter Feinberg acquired 20,000 shares of the company’s stock in a transaction on Monday, January 12th. The shares were bought at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the purchase, the director owned 135,441 shares in the company, valued at approximately $589,168.35. This represents a 17.32% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 51,819 shares of company stock worth $234,472. 22.90% of the stock is owned by insiders.

Institutional Trading of Immuneering

Institutional investors have recently made changes to their positions in the company. Sanofi purchased a new position in Immuneering during the third quarter worth about $18,960,000. Iridian Asset Management LLC CT purchased a new stake in Immuneering in the 3rd quarter valued at about $1,926,000. Monashee Investment Management LLC bought a new position in shares of Immuneering during the 3rd quarter worth approximately $2,100,000. Blue Owl Capital Holdings LP purchased a new position in shares of Immuneering in the 3rd quarter worth approximately $3,850,000. Finally, Kingsview Wealth Management LLC purchased a new stake in shares of Immuneering during the 2nd quarter valued at $47,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.